Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

[1]  T. Powles,et al.  Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  V. Jordan,et al.  Hormonal treatment of advanced breast cancer. , 1995, Surgical oncology clinics of North America.

[3]  Michael G. Ormerod,et al.  Flow Cytometry: A Practical Approach , 1994 .

[4]  M. Melamed,et al.  Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in situ end labeling of fragmented DNA. , 1994, Cytometry.

[5]  T. Powles,et al.  The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study. , 1994, European journal of cancer.

[6]  K. Maclennan,et al.  Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. , 1994, European journal of cancer.

[7]  M. Lindstrom,et al.  Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. , 1993, Cancer research.

[8]  A. Howell,et al.  Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. , 1993, British Journal of Cancer.

[9]  M. Baum,et al.  Tamoxifen alone is not adequate treatment for most elderly patients with operable breast cancer , 1992 .

[10]  M. Greco.  European Society of Mastology (EUSOMA) Today , 1992 .

[11]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[13]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[14]  F. Spyratos,et al.  Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis. , 1992, Cytometry.

[15]  M. Tubiana-Hulin,et al.  Flow cytometric DNA analysis and Samba computer assisted image analysis in the evaluation of breast carcinoma chemosensitivity , 1991 .

[16]  A. Paradiso,et al.  Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. , 1990, Cancer research.

[17]  D. Allred,et al.  Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. , 1990, Archives of surgery.

[18]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[19]  I. Ellis,et al.  Immunocytochemical localization of estrogen receptor in human breast tissue. , 1988, Cancer research.

[20]  A. Howell,et al.  Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. , 1987, Cancer research.

[21]  C. Redmond,et al.  Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Mouridsen,et al.  Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials. , 1986, NCI monographs : a publication of the National Cancer Institute.

[23]  L. Koss,et al.  Comparison of Needle Aspiration and Solid Biopsy Technics in the Flow Cytometric Study of DNA Distributions of Surgically Resected Tumors , 1985 .

[24]  C. Osborne,et al.  Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. , 1984, Cancer research.

[25]  M. Daidone,et al.  Relationship between estrogen receptors and cellular proliferation. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[26]  J. Bradbeer,et al.  Primary treatment of breast cancer in elderly women with Tamoxifen. , 1983, Clinical oncology.

[27]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[28]  Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. , 1982, British medical journal.

[29]  M. Shwartz.  Estimates of lead time and length bias in a breast cancer screening program , 1980, Cancer.

[30]  M. Namer,et al.  Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. , 1980, Cancer research.

[31]  R. Simon,et al.  Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. , 1980, European journal of cancer.

[32]  H. Mouridsen,et al.  Tamoxifen in advanced breast cancer. , 1978, Cancer treatment reviews.

[33]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[34]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[35]  E. Regnier.  Hormonal treatment of advanced breast cancer. , 1956, Minnesota medicine.